Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Chief Financial Officer | January 06, 2026 | January 08, 2026 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Chief Financial Officer | July 15, 2022 | July 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date January 06, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 121,220 |
Reported balance
After 2026-01-06 transaction · row 1
1 source rowRow 1 · 2026-01-06 · Sale · Disposed 10,591 · Balance 121,220 F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.
Protara Therapeutics, Inc.
Report date July 15, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,662 |
Reported balance
After 2022-07-15 transaction · row 1
1 source rowRow 1 · 2022-07-15 · Tax withholding · Disposed 5,081 · Balance 20,662 F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 8, 2026 21:19 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 10,591 | $6.82 | $72,227.44 |
DisclosureSEC source: 0001453687-26-000045 · wk-form4_1767907186.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,220 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 109,000 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0001453687-26-000033 · wk-form4_1767734322.xml · derivative · entry 2 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Stock · 109,000 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2027. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:18 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-26-000033 · wk-form4_1767734322.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,811 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2027. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2030. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 01:04 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 4,028 | $16.83 | $67,800.10 |
DisclosureSEC source: 0001453687-25-000035 · wk-form4_1736298282.xml · nonDerivative · entry 2 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,811 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 03, 2025 Filed Jan 8, 2025 01:04 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | SaleCommon Stock | 3,961 | $16.72 | $66,235.45 |
DisclosureSEC source: 0001453687-25-000035 · wk-form4_1736298282.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,839 F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:20 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 64,600 | $0.00 Strike: $16.93 | $0.00 |
DisclosureSEC source: 0001453687-25-000025 · wk-form4_1736198446.xml · derivative · entry 2 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,600 Underlying: Common Stock · 64,600 shares Expires 2035-01-01 F3 · derivative.exercise_date: This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:20 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-25-000025 · wk-form4_1736198446.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,800 F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. F2 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:08 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 3,110,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001453687-24-000027 · wk-form4_1704406090.xml · derivative · entry 2 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,110,000 Underlying: Common Stock · 3,110,000 shares Expires 2034-01-01 F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:08 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 2,424,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-24-000027 · wk-form4_1704406090.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,424,000 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:26 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 1,250,000 | $0.79 Strike: $1.27 | $987,500.00 |
DisclosureSEC source: 0001453687-23-000089 · wk-form4_1700087199.xml · derivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250,000 shares Expires 2032-11-27 F1 · derivative.exercise_date: This option, which provided for vesting as to 25% on November 28, 2023 with the remainder of the underlying shares vesting in 36 equal monthly installments thereafter, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc., in exchange for a cash payment of $987,500, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. Read SEC document |
| November 28, 2022 Filed Nov 30, 2022 21:40 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantEmployee Stock Option (right to buy) · Derivative | 1,250,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001453687-22-000143 · wf-form4_166984440599363.xml · derivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,250,000 Underlying: Common Stock · 1,250,000 shares Expires 2032-11-27 F1 · derivative.exercise_date: This option vests as to 25% on November 28, 2023. The remainder of the underlying shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:31 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | Tax withholdingCommon Stock | 5,081 | $3.13 | $15,903.53 |
DisclosureSEC source: 0001213900-22-040317 · ownership.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,662 F1 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on January 3, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:35 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 84,800 | $0.00 Strike: $6.90 | $0.00 |
DisclosureSEC source: 0001209191-22-001715 · doc4.xml · derivative · entry 2 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,800 Underlying: Common Stock · 84,800 shares Expires 2032-01-02 F2 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 3, 2022 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:35 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantCommon Stock | 14,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-001715 · doc4.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,581 F1 · shares: The shares being reported are being issued pursuant to restricted stock unit awards (RSUs), each of which represents a contingent right to receive one share of Issuer's common stock. The RSUs vest in equal one-third installments on the first, second and third anniversaries of January 3, 2022. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 20:05 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $19.82 | $0.00 |
DisclosureSEC source: 0001209191-21-004653 · doc4.xml · derivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-18 F1 · derivative.exercise_date: 25% of the shares vest on the one year anniversary of January 19, 2021 and 1/48th of the shares vest monthly thereafter over the next three years, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| September 22, 2020 Filed Sep 23, 2020 13:20 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | PurchaseCommon Stock | 1,481 | $16.91 | $25,037.79 |
DisclosureSEC source: 0001209191-20-051631 · doc4.xml · nonDerivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,481 F1 · price: The price reported in Column 4 is weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.885 to $16.935, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 00:51 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 94,000 | $0.00 Strike: $37.30 | $0.00 |
DisclosureSEC source: 0001209191-20-008531 · doc4.xml · derivative · entry 1 Davis Blaine · CIK 0001802188 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,000 Underlying: Common Stock · 94,000 shares Expires 2030-02-10 F1 · derivative.exercise_date: 25% of the shares subject to the option vesting upon Mr. Davis's completion of one year of service measured from the grant date and the balance of the shares vesting monthly thereafter for the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.